Healthcare Leads IPOs, while IT Leads M&A
Venture Backed IPO Pipeline also Jumps
Exit Poll report by Thomson Reuters and the National Venture Capital Association; 2013 annualized from 06/30/13
In Q2 2013, there were 84 venture backed M&A transactions with $3.0B in disclosed deal value. Number of transactions continued to decline by 8% on a rolling four quarter basis, while disclosed value also fell by 17%. The fall in disclosed value may partly be due to a decline in the percentage of deals with disclosed value from 24% to 22% over the same time period.
83% of venture backed M&A transactions were in the IT industry in Q2 2013, while 13% were Healthcare companies and the remaining 4% in other sectors. Average disclosed deal value was flat on a rolling four quarter basis at $175MM, while reaching $214MM in the Healthcare sector and $189MM in IT industries. The IT sector was boosted significantly by Yahoo!’s $1.1B acquisition of Tumblr, which was the fourth acquisition made by Yahoo! thus far in 2013.
Venture backed IPOs rebounded dramatically in Q2 2013 with 21 companies raising $2.1B. This was a 24% increase in the number of IPOs on a rolling four quarter basis. While amount raised is down 74% over the same time period, it is skewed by the unusually large $17.2B raised in Q2 2012 and is not necessarily representative of the valuation of companies at IPO. Currently, 71% of the companies that went public in Q2 2013 are trading above their offering price.
While 62% of the IPOs in Q2 2013 were Healthcare companies, Tableau Software, a Seattle based analytics software company, was the largest IPO of the quarter raising $292MM. The 11 biotechnology IPOs in Q2 2013 did represent the highest level for that sector since Q3 2000. All 11 biotechnology IPOs listed on the NASDAQ, along with three others, while six companies listed in the NYSE in Q2 2013. Currently, there are 39 venture backed companies that have filed publicly with the SEC for IPOs, representing a 59% increase over last quarter. This figure does not include companies that may have filed confidentially under the JOBS Act.
Mark Heesen, president of the NVCA, added that,
We have been predicting an IPO pickup in the second half of 2013 and it appears as if this momentum has begun, driven by the strong biotechnology offerings… While on the surface, the low acquisitions volume thus far in 2013 could appear problematic, our market intelligence is telling us that there is a great deal of inbound interest for venture backed targets, suggesting that these companies are holding out for better pricing from strategic buyers.”
The views, opinions, beliefs, conclusions, and other information expressed in this material is not given, verified, or endorsed by Square 1 Financial, Inc. or any of its affiliates. Instead, this material is solely the work of the author, and represents his views, opinions, beliefs, conclusions, and other information he wishes to present, in all cases without any manner of endorsement from or verification by Square 1 Financial, Inc. or any of its affiliates.
This material, including without limitation the statistical information herein, is provided for informational purposes only. The material is based in part upon information from third-party sources that the author believes to be reliable, but which has not been independently verified by the author, Square 1 Bank, or any Square 1 affiliate, and, as such, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal, or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to this material should be construed as a solicitation, offer, or recommendation to acquire or dispose of any investment, or to engage in any other transaction.
All material presented, unless specifically indicated otherwise, is under copyright to the author or Square 1 Financial, Inc. (or its affiliates), and is for informational purposes only. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied, or distributed to any other party, without the prior express written permission of Square 1 Financial, Inc. or the author. All trademarks, service marks, and logos used in this material are trademarks, service marks, or registered trademarks of Square 1 Financial, Inc. or one of its affiliates.
Square 1 Bank is a member of FDIC and Federal Reserve System. Square 1 Bank and the Square 1 logo are among the trademarks registered to Square 1 Financial, Inc. Square 1 Asset Management, a registered investment advisor, is a non-bank affiliate of Square 1 Bank. Products offered by Square 1 Asset Management are not FDIC insured, are not deposits or other obligations of Square 1 Bank, and may lose value.
Back To Insights